Celltrion’s Regkirona Covid-19 treatment will be used in regional treatment centers and nursing homes.
Health authorities declared that Korea’s Covid-19 risk was “high” over the past week, as pandemic indicators continue to worsen.
Regkirona, Korea’s first Covid-19 treatment, won conditional use approval from regulators in Peru, Celltrion said Monday.
Ildong Pharmaceutical signed an agreement with Osaka's Shionogi to codevelop S-217622, an oral Covid-19 treatment candidate.
Regkirona, Korea’s first Covid-19 treatment, won marketing approval from the European Commission, Celltrion said Monday.
GLS-1027, GeneOne Life Science’s Covid-19 oral treatment candidate, received approval to start Phase 2 clinical trials from the European Medicines Agency (EMA) and Bulgaria, the company said Monday.
Over 70 percent of Korea is vaccinated against Covid-19, the inoculation campaign crossing a key threshold that should lead to a return to normal in early November.
The government is planning an outpatient treatment system for Covid-19 patients to get care without having to be hospitalized.
The hair-loss-treatment market is growing fast as more younger Koreans are balding. A total of 233,194 people visited hospitals for hair loss problems last year, and of them around 43 percent were people in their 20s and 30s, according to data...
Game-changing Covid oral treatments being announced by multinationals are knocking the stuffing out of biopharmaceuticals, both those pursuing vaccine strategies and those looking for oral remedies of their own for the virus.